Blood biomarkerssuch as pTau181, Aβ42/40, NfL, and GFAP have improved our understanding ofdementia pathophysiology, however, few studies have explored how specific blood pressuremetrics relate to biomarker levels, which could inform personalized dementia preventionstrategies as these biomarkers move into clinic. This evidence concerns the gene GFAP and dementia.